Intravenous Infusion Pumps Market Trends
The size of the global intravenous infusion pumps market was valued at USD 6.15 billion in 2024 and is expected to grow at a CAGR of 8.5% during the period from 2025 to 2035. The rising prevalence of diseases like cancer, diabetes, cardiovascular diseases, and respiratory diseases requires precise delivery of drugs and therapies. Infusion pumps are crucial in this regard, providing accurate dosages of essential treatments like chemotherapy, antibiotics, and nutritional fluids. As these chronic conditions increase, the market for infusion pumps keeps growing, which speaks volumes about their pivotal position in successful disease management.
Intravenous infusion pumps are used to administer drugs, hormones, and nutritional fluids into the body via veins in measured amounts. Intravenous infusion pumps are used extensively in healthcare settings such as hospitals, nursing homes, and homes. An experienced operator operates the pump by programming the rate and duration of fluid infusion through built-in software. Intravenous infusion pumps can administer nutrients, hormones, antibiotics, cancer chemotherapy medications, and analgesics.
The key drivers of the market growth are increasing cases of chronic illnesses, high geriatric population growth, increasing demand for ambulatory infusion pumps, and the increasing number of people who are being operated upon. Intravenous infusion pumps are used mainly to administer critical fluids, including high-risk medication. Most infusion pumps are equipped with safety features and built-in alarms for operator notification that are intended to activate in the event of a problem. There are many conditions, including immune deficiency, cancer, and congestive heart failure, that cannot be treated with oral medications and must be treated with infusion therapy.
As the population ages, older adults are more susceptible to chronic diseases that require complex medication regimens. Infusion pumps prove most beneficial within the out-patient and home care settings, giving safe and accurate drug infusion to elderly patients. The population trend towards increasing aging highlights the use of infusion pumps, whereby health care providers are able to best meet the needs of this fragile population in their individual need. According to the World Health Organization, the life expectancy at birth improved to 73.3 years in the year 2024 from a growth of 8.4 years since 1995. In addition, the population of people aged 60 and older around the globe will grow from 1.1 billion in 2023 to 1.4 billion in the year 2030.
Improvements in infusion pump capabilities also substantiate the market demand. The creation of smart infusion pumps with wireless connectivity, electronic health record (EHR) integration, and programmatic programming enhances patient safety and operational excellence. These advanced functions minimize medical mistakes, simplify workflow, and allow for adherence to treatment protocols, prompting healthcare facilities to invest in these high-technology devices. Consequently, the integration of state-of-the-art technology into infusion pumps is providing opportunities for more practice in clinical environments.
Report Coverage & Deliverables
PDF report & online dashboard will help you understand
- Competitive benchmarking
- Historical data & forecasts
- Company revenue shares
- Regional opportunities
- Latest trends & dynamics
Market Concentration & Characteristics
The industry growth stage is high, and the pace of the market growth is accelerating. The emergence of smart infusion pumps equipped with advanced software minimizes medication errors through features such as drug libraries and wireless connectivity, thus enhancing workflow efficiency and safety in clinical settings.
Mergers and acquisitions are significantly prevalent within the parent market as companies strive to enhance their technological capabilities and market presence. Major industry players such as ICU Medical and Baxter International engage in strategic partnerships and acquisitions, facilitating innovation, accelerated product development, and enhanced distribution channels to meet rising market demands.
Regulatory frameworks play a crucial role in the intravenous infusion pump market by ensuring the safety and efficacy of products. Stringent, timely approvals from entities such as the U.S. Food and Drug Administration (FDA) enhance market acceptance and product development, thereby influencing innovation trajectories within the industry. In August 2024, the FDA expanded the Insulet SmartAdjust technology’s indications, enabling automated insulin dosing for adults with type 2 diabetes in the U.S.
Though intravenous infusion pumps are essential for accurate drug delivery, alternatives such as manual infusion techniques, syringe pumps, and wearable delivery systems exist. However, manual methods lack the precision of smart pumps, leading to their decline in favor of advanced solutions, which remain vital for continuous therapy in home healthcare settings.
Demographic shifts, healthcare investments, technological progress, and facilitative regulatory frameworks determine regional expansion in the market. North America and Europe currently exhibit market dominance in innovation, whereas the Asia Pacific region demonstrates the most rapid growth, attributed to its dynamic healthcare evolution and demographic transformations. Emerging markets are anticipated to experience future market expansion with improvements in infrastructure and access to sophisticated therapeutic modalities.
Product Insights
Volumetric infusion pumps were the market leaders and had a market share of 16.8% in 2024. Volumetric infusion pumps, employing electronic peristaltic pressure for precise and continuous fluid delivery, play an important role in many healthcare facilities for the delivery of drugs, nutrients, and analgesics. Their effectiveness in delivering large volumes with accuracy is essential in the treatment of chronic diseases like cancer and diabetes and in surgical interventions. The incorporation of innovative technologies and libraries of drugs by major companies further increases their applicability.
Insulin infusion pumps are likely to achieve the highest CAGR of 9.1% during the forecast period.Global increasing prevalence of diabetes, mainly due to aging, poor lifestyles, and growing obesity, has stimulated insulin pump demand. WHO statistics released in March 2024 revealed that, in 2022, an estimated 43.0% of adults were overweight and 16.0% obese, both of which are major risk factors for type 2 diabetes.
Insulin pumps have advantages over conventional delivery systems by delivering continuous subcutaneous insulin infusion (CSII) that provides improved glycemic control. Next-generation pumps with continuous glucose monitoring and AI-driven adjustment further enhance patient outcomes, driving the growth of home-based diabetes care solutions.
The ambulatory infusion pumps, through which liquid medications and nutrients are delivered to a patient in cases of emergencies and chronic diseases, had a strong market share in 2024. The pumps are highly popular for the administration of nutrients and drugs. Availability of other pumps like patient-controlled analgesia (PCA) pumps, insulin pumps, and smart pumps will add to the supplementary growth of this segment. Increased demand for syringe and enteral pumps is the driving force behind the growing inclination towards the intravenous infusion pump, thus fostering segment growth.
Disease Indication Insights
Pediatrics/neonatology led the market with a revenue share of 26.4% in 2024. The market has been segmented based on disease indication into chemotherapy, diabetes, gastroenterology, analgesia/pain management, pediatrics/neonatology, hematology, and others. According to the CDC, 1 in every 33 babies born in the U.S. is diagnosed with a congenital disability each year. Neonatology focuses on acute conditions in newborns, such as prematurity and congenital malformations. Effective, cost-efficient care and proper nutrition post-birth can reduce preterm births by nearly three-quarters. Moreover, older children face diseases such as neuroblastoma and Gaucher disease, which necessitate advanced infusion pumps for accurate medication delivery and to reduce overdose risks.
Chemotherapy is projected to grow at the fastest CAGR of 9.7% over the forecast period. In 2024, the American Cancer Society projected over 2 million new cancer cases and 611,720 cancer deaths in the U.S. While 30%-50 % of cancers can be prevented through risk mitigation and early diagnosis, treatment for malignant tumors often requires chemotherapy, administered intravenously or via capsules. In November 2024, a randomized phase 2 clinical trial by the University of Iowa Health Care demonstrated that adding high-dose intravenous vitamin C to chemotherapy doubled the overall survival of late-stage metastatic pancreatic cancer patients from eight months to 16 months. Such developments necessitate precise drug delivery through intravenous infusion pumps, driving market growth due to the increasing cancer prevalence.
The hematology segment is estimated to grow significantly over the forecast period. With the rising incidences of surgeries and blood cancer (hemophilia), the demand for intravenous infusion pumps has surged in hematology. These pumps are used for treatments such as blood transfusion, which is expected to increase in the coming years. Intravenous pumps are used for hematology as they are the only way blood can be transfused into a patient’s body in a precise, compact, and continuous manner. Moreover, it can regulate manual control or in an automated manner, avoiding the risk of failure during the treatment.
Regional Insights
North America intravenous infusion pumps market held the highest revenue share in the global market at 50.8% in 2024. Rising Incidence of chronic diseases, a growing number of surgical procedures conducted, highly developed & rising R&D, and rising use of advanced technology in infusion pumps drove the growth of the intravenous pumps market in this region.
Mackenzie Health (Canada) introduced BD Alaris EMR Interoperability, a first of its kind technology in Canada, in April 2024. This platform allows two-way communication between IV pumps and EMRs of patients and is designed to lower medication errors and make workflows easier.
U.S. Intravenous Infusion Pumps Market Trends
The U.S. intravenous infusion pumps market led the North America market with a revenue of 87.6% in 2024, driven by the high incidence of chronic diseases, such as diabetes and cancer. The high rates of diabetes in the country are attributed to unhealthy lifestyle and stressful working conditions. Based on the Heart Failure Society of America's (HFSA) report on Heart Failure Epidemiology and Outcomes Statistics 2024, nearly 6.7 million Americans above the age of 20 have heart failure now and is anticipated to grow up to 8.7 million by 2030. Thus, increasing cardiovascular and chronic respiratory diseases, population aging, and rising surgical interventions are likely to increase demand for infusion pumps. Increased government regulations and better standards of care are also contributing to market growth, in addition to new product launches and FDA approvals.
Europe Intravenous Infusion Pumps Market Trends
Europe intravenous infusion pumps market held substantial market share in 2024. Most European countries boast well-developed healthcare infrastructures, facilitating the adoption of advanced patient care technologies. The market was driven by a growing burden of chronic diseases such as cancer and diabetes, an increasing number of surgical procedures, a rapid rise in the geriatric population, and significant government support.
Asia Pacific Intravenous Infusion Pumps Market Trends
Asia Pacific intravenous infusion pumps market is expected to register the fastest CAGR of 9.0% in the forecast period. Asian countries are population-dense with an elevated burden of chronic diseases such as diabetes, cardiovascular illnesses, and cancer. These countries are also popular for their low cost of treatment and surgeries, thus being a preferred market for medical tourism. Countries such as China, Japan, and India are emerging economies with well-developed healthcare infrastructure and facilities.
Japan's intravenous infusion pumps market is projected to grow at the fastest CAGR over the forecast period. The country is experiencing a rising median age due to declining mortality and increased life expectancy. This demographic shift has led to a growing prevalence of chronic diseases, highlighting the need for advanced infusion therapies.
Key Intravenous Infusion Pumps Company Insights
The market operators are strategically deploying drivers like a change in technology, automation, standardized dosing, and widespread adoption of cutting-edge healthcare technology for better healthcare services. In addition, prominent players tend to go for geographic expansion to preserve market share and use mergers, acquisitions, and new product developments to expand their portfolio.
Fresenius Kabi AG is a worldwide producer of intravenous infusion pumps, offering a complete range of syringe and volumetric pumps to deliver drugs and fluids precisely in hospital and ambulatory environments. Its devices feature safety technologies, medication error preventing software, and IV disposables and accessories.
Tandem Diabetes Care, Inc. designs insulin infusion pumps for the proper management of diabetes. Its ground-breaking tslim X2 pump, with Control-IQ technology, provides intuitive, connected insulin infusion systems that include continuous glucose monitoring and automated dosing of insulin for people with diabetes.
Key Intravenous Infusion Pumps Companies
The following are the leading companies in the intravenous infusion pumps market. These companies collectively hold the largest market share and dictate industry trends.
- Baxter
- B. Braun Medical Inc.
- Medtronic
- Micrel Medical Devices SA
- Boston Scientific Corporation
- Cardinal Health
- Fresenius Kabi AG
- ICU Medical, Inc.
- F. Hoffmann-La Roche Ltd
- Tandem Diabetes Care, Inc.
- Terumo Corporation
- Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
- Moog Inc.
- IRadimed Corporation
Recent Developments
-
In April 2025, Tandem Diabetes Care launched the Control-IQ+ insulin delivery technology in the U.S. This automated system expands accessibility to adults with type 2 diabetes and children aged two and older with type 1 diabetes.
-
In April 2025, ICU Medical received FDA 510(k) clearance for its new Plum Solo single-channel infusion pump and updated Plum Duo, expanding its IV Performance Platform with enhanced accuracy and data capabilities.
-
In November 2024, Boston Scientific announced an agreement to acquire Intera Oncology, aiming to broaden the company’s interventional oncology portfolio with Intera’s hepatic artery infusion pump technology for treating liver-dominant metastases.
-
In November 2024, ICU Medical, Inc. and Otsuka Pharmaceutical Factory (Japan) announced a joint venture to bolster IV solutions manufacturing and innovation within the North American market.
-
In October 2024, B. Braun Medical announced plans to increase its intravenous saline fluids production by 20% at its Irvine, California, and Daytona Beach, Florida facilities to address supply demands.
-
In April 2024, Baxter obtained FDA clearance for its Dose IQ Safety Software and Novum IQ large volume infusion pump, integrating both infusion modalities.
-
In January 2024, embecta Corp. announced the submission of a 510(k) premarket filing to the U.S. FDA for its proprietary disposable insulin delivery patch pump, designed to address the needs of individuals with type 2 diabetes.
Intravenous Infusion Pumps Market Report Scope
|
Report Attribute |
Details |
|
Market size value in 2025 |
USD 6.64 billion |
|
Revenue forecast in 2030 |
USD 9.98 billion |
|
Growth rate |
CAGR of 8.5% from 2025 to 2035 |
|
Base year for estimation |
2024 |
|
Historical data |
2018 - 2023 |
|
Forecast period |
2025 - 2035 |
|
Quantitative units |
Revenue in USD million/billion and CAGR from 2025 to 2035 |
|
Report coverage |
Revenue forecast, company ranking, competitive landscape, growth factors, trends |
|
Segments covered |
Product, disease indication, region |
|
Regional scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country scope |
U.S.; Canada; Mexico; UK; Germany; France; Italy; Spain; Denmark; Sweden; Norway; China; Japan; India; Australia; South Korea; Thailand; Brazil; Argentina; South Africa; Saudi Arabia; UAE; Kuwait |
|
Key companies profiled |
Baxter; B. Braun Medical Inc.; Medtronic; Micrel Medical Devices SA; Boston Scientific Corporation; Cardinal Health; Fresenius Kabi AG; ICU Medical, Inc.; F. Hoffmann-La Roche Ltd; Tandem Diabetes Care, Inc.; Terumo Corporation; Shenzhen Mindray Bio-Medical Electronics Co., Ltd.; Moog Inc.; IRadimed Corporation |
|
Customization scope |
Free report customization (equivalent up to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope. |
|
Pricing and purchase options |
Avail customized purchase options to meet your exact research needs. Explore purchase options |
Global Intravenous Infusion Pumps Market Report Segmentation
Product Outlook (Revenue, USD Million, 2018 - 2035)
-
-
Volumetric Infusion Pumps
-
Syringe Infusion Pumps
-
Insulin Infusion Pumps
-
Enteral Infusion Pumps
-
Ambulatory Infusion Pumps
-
Patient-Controlled Analgesia Infusion Pumps
-
Implantable Infusion Pumps
-
Others
-
-
Disease Indication Outlook (Revenue, USD Million, 2018 - 2035)
-
Chemotherapy
-
Diabetes
-
Gastroenterology
-
Analgesia/Pain Management
-
Pediatrics/Neonatology
-
Hematology
-
Others
-
-
Regional Outlook (Revenue, USD Million, 2018 - 2035)
-
North America
-
U.S.
-
Canada
-
Mexico
-
-
Europe
-
UK
-
Germany
-
France
-
Italy
-
Spain
-
Denmark
-
Sweden
-
Norway
-
-
Asia Pacific
-
China
-
Japan
-
India
-
Australia
-
South Korea
-
Thailand
-
-
Latin America
-
Brazil
-
Argentina
-
-
Middle East & Africa
-
South Africa
-
Saudi Arabia
-
UAE
-
Kuwait
-
-
Related Reports
FAQ'S
For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:
Within 24 to 48 hrs.
You can contact Sales team (sales@marketinsightsresearch.com) and they will direct you on email
You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.
Discounts are available.
Hard Copy